osteolectin Search Results


human osteolectin clec11a scgf α  (R&D Systems)
91
R&D Systems human osteolectin clec11a scgf α
Human Osteolectin Clec11a Scgf α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/osteolectin/Recombinant+Human+SCGF-alpha%2FCLEC11a+Protein/pmc08237660-151-9-11
Average 91 stars, based on 1 article reviews
human osteolectin clec11a scgf α - by Bioz Stars, 2026-10
91/100 stars
  Buy from Supplier
cleancap cas9 mrna  (TriLink)
90
TriLink cleancap cas9 mrna
<t>Osteolectin</t> deficiency attenuates PTH-induced Wnt signaling. Bone marrow stromal cells cultured from Osteolectin -deficient ( Oln −/− ) or littermate control (WT) mice were treated with PTH (10 nM), SOSTi (10 ng/mL), or PBS (control) in osteogenic differentiation medium. ( A – D ) Bone marrow stromal cells were lysed 60 min after treatment and immunoblotted for β-actin, GSK3, phospho-GSK3 (p-GSK3), Smad1, phospho-Smad1 (p-Smad1), P38, and phospho-P38 (p-P38) (representative of three independent experiments). ( B ) Phospho-GSK3 levels normalized to total GSK3 levels. ( C ) Phospho-Smad1 levels normalized to total Smad1 levels. ( D ) Phospho-P38 levels normalized to total P38 levels. ( E – G ) Bone marrow stromal cells were lysed 24 h after treatment and immunoblotted for β-actin, β-catenin, and osteolectin (representative of three independent experiments). ( F ) β-Catenin levels normalized to β-actin levels. ( G ) Osteolectin levels normalized to β-actin levels. ( H–K ) Bone marrow stromal cells were lysed 3 d after treatment and analyzed by qRT-PCR to assess Osteolectin ( H ) and Wnt target gene transcript levels including Alpl ( I ), Lef1 ( J ), and Runx2 ( K ). ( L – P ) C ontrol bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PBS or BML-284, a Wnt agonist, then lysed 24 h later and immunoblotted for β-actin, β-catenin, and osteolectin ( L ) or analyzed 3 d later by qRT-PCR to assess Osteolectin ( M ) or Wnt target gene transcript levels including Alpl ( N ), Lef1 ( O ), and Runx2 ( P ) ( n = 3 independent experiments). ( Q and R ) Oln −/− or control bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PTH or PBS for 14 d and stained with Alizarin red S ( n = 3 independent experiments). ( S ) The effect of PTH on Wnt pathway activation and osteogenic differentiation are mediated partly by osteolectin (Oln). All data represent mean ± SD. Statistical significance was assessed using paired sample two-way ANOVAs followed by Dunnett’s (comparing treatments in B – D , F – K , and R ), Holm–Sidak’s (comparing genotypes in B – D and F – K ) or Sidak’s ( M – P and comparing genotypes in R ) multiple comparisons tests (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
Cleancap Cas9 Mrna, supplied by TriLink, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/osteolectin/cas9+mrna/pmc08237660-115-2-8
Average 90 stars, based on 1 article reviews
cleancap cas9 mrna - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
anti mouse osteolectin antibody af3729  (R&D Systems)
94
R&D Systems anti mouse osteolectin antibody af3729
<t>Osteolectin</t> deficiency attenuates PTH-induced Wnt signaling. Bone marrow stromal cells cultured from Osteolectin -deficient ( Oln −/− ) or littermate control (WT) mice were treated with PTH (10 nM), SOSTi (10 ng/mL), or PBS (control) in osteogenic differentiation medium. ( A – D ) Bone marrow stromal cells were lysed 60 min after treatment and immunoblotted for β-actin, GSK3, phospho-GSK3 (p-GSK3), Smad1, phospho-Smad1 (p-Smad1), P38, and phospho-P38 (p-P38) (representative of three independent experiments). ( B ) Phospho-GSK3 levels normalized to total GSK3 levels. ( C ) Phospho-Smad1 levels normalized to total Smad1 levels. ( D ) Phospho-P38 levels normalized to total P38 levels. ( E – G ) Bone marrow stromal cells were lysed 24 h after treatment and immunoblotted for β-actin, β-catenin, and osteolectin (representative of three independent experiments). ( F ) β-Catenin levels normalized to β-actin levels. ( G ) Osteolectin levels normalized to β-actin levels. ( H–K ) Bone marrow stromal cells were lysed 3 d after treatment and analyzed by qRT-PCR to assess Osteolectin ( H ) and Wnt target gene transcript levels including Alpl ( I ), Lef1 ( J ), and Runx2 ( K ). ( L – P ) C ontrol bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PBS or BML-284, a Wnt agonist, then lysed 24 h later and immunoblotted for β-actin, β-catenin, and osteolectin ( L ) or analyzed 3 d later by qRT-PCR to assess Osteolectin ( M ) or Wnt target gene transcript levels including Alpl ( N ), Lef1 ( O ), and Runx2 ( P ) ( n = 3 independent experiments). ( Q and R ) Oln −/− or control bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PTH or PBS for 14 d and stained with Alizarin red S ( n = 3 independent experiments). ( S ) The effect of PTH on Wnt pathway activation and osteogenic differentiation are mediated partly by osteolectin (Oln). All data represent mean ± SD. Statistical significance was assessed using paired sample two-way ANOVAs followed by Dunnett’s (comparing treatments in B – D , F – K , and R ), Holm–Sidak’s (comparing genotypes in B – D and F – K ) or Sidak’s ( M – P and comparing genotypes in R ) multiple comparisons tests (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
Anti Mouse Osteolectin Antibody Af3729, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/osteolectin/Mouse+SCGF%2FCLEC11a+Antibody/pmc08237660-176-3-14
Average 94 stars, based on 1 article reviews
anti mouse osteolectin antibody af3729 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
goat anti mouse osteolectin antibody  (R&D Systems)
94
R&D Systems goat anti mouse osteolectin antibody
<t>Osteolectin</t> deficiency attenuates PTH-induced Wnt signaling. Bone marrow stromal cells cultured from Osteolectin -deficient ( Oln −/− ) or littermate control (WT) mice were treated with PTH (10 nM), SOSTi (10 ng/mL), or PBS (control) in osteogenic differentiation medium. ( A – D ) Bone marrow stromal cells were lysed 60 min after treatment and immunoblotted for β-actin, GSK3, phospho-GSK3 (p-GSK3), Smad1, phospho-Smad1 (p-Smad1), P38, and phospho-P38 (p-P38) (representative of three independent experiments). ( B ) Phospho-GSK3 levels normalized to total GSK3 levels. ( C ) Phospho-Smad1 levels normalized to total Smad1 levels. ( D ) Phospho-P38 levels normalized to total P38 levels. ( E – G ) Bone marrow stromal cells were lysed 24 h after treatment and immunoblotted for β-actin, β-catenin, and osteolectin (representative of three independent experiments). ( F ) β-Catenin levels normalized to β-actin levels. ( G ) Osteolectin levels normalized to β-actin levels. ( H–K ) Bone marrow stromal cells were lysed 3 d after treatment and analyzed by qRT-PCR to assess Osteolectin ( H ) and Wnt target gene transcript levels including Alpl ( I ), Lef1 ( J ), and Runx2 ( K ). ( L – P ) C ontrol bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PBS or BML-284, a Wnt agonist, then lysed 24 h later and immunoblotted for β-actin, β-catenin, and osteolectin ( L ) or analyzed 3 d later by qRT-PCR to assess Osteolectin ( M ) or Wnt target gene transcript levels including Alpl ( N ), Lef1 ( O ), and Runx2 ( P ) ( n = 3 independent experiments). ( Q and R ) Oln −/− or control bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PTH or PBS for 14 d and stained with Alizarin red S ( n = 3 independent experiments). ( S ) The effect of PTH on Wnt pathway activation and osteogenic differentiation are mediated partly by osteolectin (Oln). All data represent mean ± SD. Statistical significance was assessed using paired sample two-way ANOVAs followed by Dunnett’s (comparing treatments in B – D , F – K , and R ), Holm–Sidak’s (comparing genotypes in B – D and F – K ) or Sidak’s ( M – P and comparing genotypes in R ) multiple comparisons tests (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).
Goat Anti Mouse Osteolectin Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/osteolectin/Mouse+SCGF%2FCLEC11a+Antibody/pmc10235998__pnas__2220159120__sapp-23-9-31
Average 94 stars, based on 1 article reviews
goat anti mouse osteolectin antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
human clec11a elisa kit picokine  (Boster Bio)
N/A
Human CLEC11A ELISA Kit PicoKine® (96 Tests). Quantitate Human CLEC11A in cell culture supernatants, serum and plasma (heparin, EDTA). Sensitivity: 50pg/ml. The brand Picokine indicates this is a premium quality ELISA kit. Each Picokine kit
   Buy from Supplier
human clec11a ez-set elisa kit  (Boster Bio)
N/A
Human CLEC11A ELISA Kit EZ-Set™ (DIY Antibody Pairs) (antibody pairs and standards for assay development). Quantitate Human CLEC11A in cell culture supernatants, serum and plasma (heparin, EDTA).
   Buy from Supplier
human c-type lectin domain family 11 member a  (Shanghai Korain Biotech Co Ltd)
N/A
C-type lectin domain family 11 member A is a protein that in humans is encoded by the CLEC11A gene.
   Buy from Supplier

Image Search Results


Osteolectin deficiency attenuates PTH-induced Wnt signaling. Bone marrow stromal cells cultured from Osteolectin -deficient ( Oln −/− ) or littermate control (WT) mice were treated with PTH (10 nM), SOSTi (10 ng/mL), or PBS (control) in osteogenic differentiation medium. ( A – D ) Bone marrow stromal cells were lysed 60 min after treatment and immunoblotted for β-actin, GSK3, phospho-GSK3 (p-GSK3), Smad1, phospho-Smad1 (p-Smad1), P38, and phospho-P38 (p-P38) (representative of three independent experiments). ( B ) Phospho-GSK3 levels normalized to total GSK3 levels. ( C ) Phospho-Smad1 levels normalized to total Smad1 levels. ( D ) Phospho-P38 levels normalized to total P38 levels. ( E – G ) Bone marrow stromal cells were lysed 24 h after treatment and immunoblotted for β-actin, β-catenin, and osteolectin (representative of three independent experiments). ( F ) β-Catenin levels normalized to β-actin levels. ( G ) Osteolectin levels normalized to β-actin levels. ( H–K ) Bone marrow stromal cells were lysed 3 d after treatment and analyzed by qRT-PCR to assess Osteolectin ( H ) and Wnt target gene transcript levels including Alpl ( I ), Lef1 ( J ), and Runx2 ( K ). ( L – P ) C ontrol bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PBS or BML-284, a Wnt agonist, then lysed 24 h later and immunoblotted for β-actin, β-catenin, and osteolectin ( L ) or analyzed 3 d later by qRT-PCR to assess Osteolectin ( M ) or Wnt target gene transcript levels including Alpl ( N ), Lef1 ( O ), and Runx2 ( P ) ( n = 3 independent experiments). ( Q and R ) Oln −/− or control bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PTH or PBS for 14 d and stained with Alizarin red S ( n = 3 independent experiments). ( S ) The effect of PTH on Wnt pathway activation and osteogenic differentiation are mediated partly by osteolectin (Oln). All data represent mean ± SD. Statistical significance was assessed using paired sample two-way ANOVAs followed by Dunnett’s (comparing treatments in B – D , F – K , and R ), Holm–Sidak’s (comparing genotypes in B – D and F – K ) or Sidak’s ( M – P and comparing genotypes in R ) multiple comparisons tests (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin

doi: 10.1073/pnas.2026176118

Figure Lengend Snippet: Osteolectin deficiency attenuates PTH-induced Wnt signaling. Bone marrow stromal cells cultured from Osteolectin -deficient ( Oln −/− ) or littermate control (WT) mice were treated with PTH (10 nM), SOSTi (10 ng/mL), or PBS (control) in osteogenic differentiation medium. ( A – D ) Bone marrow stromal cells were lysed 60 min after treatment and immunoblotted for β-actin, GSK3, phospho-GSK3 (p-GSK3), Smad1, phospho-Smad1 (p-Smad1), P38, and phospho-P38 (p-P38) (representative of three independent experiments). ( B ) Phospho-GSK3 levels normalized to total GSK3 levels. ( C ) Phospho-Smad1 levels normalized to total Smad1 levels. ( D ) Phospho-P38 levels normalized to total P38 levels. ( E – G ) Bone marrow stromal cells were lysed 24 h after treatment and immunoblotted for β-actin, β-catenin, and osteolectin (representative of three independent experiments). ( F ) β-Catenin levels normalized to β-actin levels. ( G ) Osteolectin levels normalized to β-actin levels. ( H–K ) Bone marrow stromal cells were lysed 3 d after treatment and analyzed by qRT-PCR to assess Osteolectin ( H ) and Wnt target gene transcript levels including Alpl ( I ), Lef1 ( J ), and Runx2 ( K ). ( L – P ) C ontrol bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PBS or BML-284, a Wnt agonist, then lysed 24 h later and immunoblotted for β-actin, β-catenin, and osteolectin ( L ) or analyzed 3 d later by qRT-PCR to assess Osteolectin ( M ) or Wnt target gene transcript levels including Alpl ( N ), Lef1 ( O ), and Runx2 ( P ) ( n = 3 independent experiments). ( Q and R ) Oln −/− or control bone marrow stromal cells cultured in osteogenic differentiation medium were treated with PTH or PBS for 14 d and stained with Alizarin red S ( n = 3 independent experiments). ( S ) The effect of PTH on Wnt pathway activation and osteogenic differentiation are mediated partly by osteolectin (Oln). All data represent mean ± SD. Statistical significance was assessed using paired sample two-way ANOVAs followed by Dunnett’s (comparing treatments in B – D , F – K , and R ), Holm–Sidak’s (comparing genotypes in B – D and F – K ) or Sidak’s ( M – P and comparing genotypes in R ) multiple comparisons tests (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).

Article Snippet: To generate Osteolectin flox mice, CleanCap Cas9 mRNA (TriLink) and single-guide RNAs (transcribed using MEGAshortscript Kit [Ambion], purified using the MEGAclear Kit [Ambion]), and recombineering single-strand DNA were microinjected into C57BL/ K a zygotes.

Techniques: Cell Culture, Control, Quantitative RT-PCR, Staining, Activation Assay

PTH and osteolectin additively increase trabecular bone volume. ( A ) Representative microCT images of cortical bone in the midfemur diaphysis of male wild-type (WT) mice treated with PBS, PTH, osteolectin (Oln), or the combination of PTH plus osteolectin for 3 mo. ( B – D ) MicroCT analysis of the cortical bone volume/total volume ( B ), cortical thickness ( C ), and cortical bone mineral density ( D ) in the midfemur diaphysis of these mice. ( E ) Representative microCT images of trabecular bone in the distal femur metaphysis of male mice. ( F – K ) MicroCT analysis of the trabecular bone volume/total volume ( F ), trabecular number ( G ), trabecular thickness ( H ), trabecular spacing ( I ), trabecular connectivity density ( J ), and trabecular bone mineral density ( K ) in the distal femur metaphysis of these mice. For all experiments, n = 5 mice per group. All data represent mean ± SD. Statistical significance was assessed using one-way ANOVAs ( C , F , G , and J ) or two-way ANOVAs ( D , H , I , and K ) followed by Tukey’s multiple comparisons tests (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).

Journal: Proceedings of the National Academy of Sciences of the United States of America

Article Title: The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin

doi: 10.1073/pnas.2026176118

Figure Lengend Snippet: PTH and osteolectin additively increase trabecular bone volume. ( A ) Representative microCT images of cortical bone in the midfemur diaphysis of male wild-type (WT) mice treated with PBS, PTH, osteolectin (Oln), or the combination of PTH plus osteolectin for 3 mo. ( B – D ) MicroCT analysis of the cortical bone volume/total volume ( B ), cortical thickness ( C ), and cortical bone mineral density ( D ) in the midfemur diaphysis of these mice. ( E ) Representative microCT images of trabecular bone in the distal femur metaphysis of male mice. ( F – K ) MicroCT analysis of the trabecular bone volume/total volume ( F ), trabecular number ( G ), trabecular thickness ( H ), trabecular spacing ( I ), trabecular connectivity density ( J ), and trabecular bone mineral density ( K ) in the distal femur metaphysis of these mice. For all experiments, n = 5 mice per group. All data represent mean ± SD. Statistical significance was assessed using one-way ANOVAs ( C , F , G , and J ) or two-way ANOVAs ( D , H , I , and K ) followed by Tukey’s multiple comparisons tests (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001).

Article Snippet: To generate Osteolectin flox mice, CleanCap Cas9 mRNA (TriLink) and single-guide RNAs (transcribed using MEGAshortscript Kit [Ambion], purified using the MEGAclear Kit [Ambion]), and recombineering single-strand DNA were microinjected into C57BL/ K a zygotes.

Techniques: